Journal
ONCOIMMUNOLOGY
Volume 2, Issue 11, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.26967
Keywords
MDSC; listeria; cancer vaccine; tumor microenvironment; targeted therapy
Categories
Funding
- NIA NIH HHS [R01 AG023096, T32 AG023475] Funding Source: Medline
Ask authors/readers for more resources
While conventional anticancer therapies, including surgical resection, radiotherapy, and/or chemotherapy, are relatively efficient at eliminating primary tumors, these treatment modalities are largely ineffective against metastases. At least in part, this reflects the rather inefficient delivery of conventional anticancer agents to metastatic lesions. We have recently demonstrated that myeloid-derived suppressor cells (MDSCs) can be used as cellular missiles to selectively deliver a radioisotope-coupled attenuated variant of Listeria monocytogenes to both primary and metastatic neoplastic lesions in mice with pancreatic cancer. This novel immunotherapeutic intervention robustly inhibited tumor growth while promoting a dramatic decrease in the number of metastases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available